{
  "id": "adv_mhgap#risk_safety_53008237",
  "content": "treatment of drug use disorders (147) (see Box 3.1).\nhistory of psychosis). The medicine choice should\nconsider, besides effectiveness, factors such as\nResearch gaps\ndemographic characteristics (e.g. higher risks\ny All studies were done in HICs. Further research is\nand side-effects that may be associated with\nneeded in LMICs.\npregnancy or older age), side-effects profiles\ny Most trials assessed adult populations, excluding\n(e.g. cardiovascular effects, psychosis/mania,\nindividuals under 18 or above 70 years old. Further\nweight gain) and availability (e.g. continuous\nresearch is needed on adolescents and older adults.\navailability, costs).\ny Evidence on prescription amphetamines/\ny Comorbidities and complications, namely\ndexamphetamine is very limited, as few studies\ncardiovascular events and psychosis, should\nassessed them for methamphetamine dependence,\nbe carefully monitored during the treatment of\nwith heterogeneous outcomes. Evidence on\nmethamphetamine dependence.\nprescription amphetamines for cocaine dependence\nis limited by earlier trials that used very small doses.\nFurther research is needed.\n68\n3. Recommendations\nDRU3. Which psychosocial interventions are effective in the\ntreatment of stimulant dependence for adults?\nRecommendation (update): Psychosocial interventions – namely cognitive behavioural therapy (CBT)\nand contingency management – should be offered to adults with cocaine and\nstimulant dependence.\nStrength of recommendation: Strong\nCertainty of evidence: Low",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Risk Safety treatment of drug use disorders (147) (see Box 3.1).\nhistory of psychosis). The medicine choice should\nconsider, besides effectiveness, factors such as\nResearch gaps\ndemographic characteristics (e.g. higher risks\ny All studies were done in HICs. Further research is\nand side-effects that may be associated with\nneeded in LMICs.\npregnancy or older age), side-effects profiles\ny Most trials assessed adult populations, excluding\n(e.g. cardiovascular effects, psychosis/mania,\nindividuals under 18 or above 70 years old. Further\nweight gain) and availability (e.g. continuous\nresearch is needed on adolescents and older adults.\navailability, costs).\ny Evidence on prescription amphetamines/\ny Comorbidities and complications, namely\ndexamphetamine is very limited, as few studies\ncardiovascular events and psychosis, should\nassessed them for methamphetamine dependence,\nbe carefully monitored during the treatment of\nwith heterogeneous outcomes. Evidence on\nmethamphetamine dependence.\nprescription amphetamines for cocaine dependence\nis limited by earlier trials that used very small doses.\nFurther research is needed.\n68\n3. Recommendations\nDRU3. Which psychosocial interventions are effective in the\ntreatment of stimulant dependence for adults?\nRecommendation (update): Psychosocial interventions – namely cognitive behavioural therapy (CBT)\nand contingency management – should be offered to adults with cocaine and\nstimulant dependence.\nStrength of recommendation: Strong\nCertainty of evidence: Low Treatment of drug use disorders (147) (see box 3.1). history of psychosis)."
}